Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease

HIGHLIGHTS

• who: Wei-Chieh Lee from the (UNIVERSITY) have published the research: Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease, in the Journal: (JOURNAL)
• what: Baseline characteristics in the sacubitril/valsartan and ACEI/ARB groups before and after propensity score matching This study enrolled 3735 participants, and their baseline characteristics and medication use are shown in Table 1. This study provided important data to fill the gap, in terms of all-cause mortality, in symptomatic patients with HFrEF and CKD. Study limitations This study has several . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.